We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Expression of Neprilysin in Skeletal Muscle Reduces Amyloid Burden in a Transgenic Mouse Model of Alzheimer Disease.
- Authors
Yinxing Liu; Studzinski, Christa; Beckett, Tina; Hanjun Guan; Hersh, Matthew A.; Murphy, M. Paul; Klein, Ronald; Hersh, Louis B.
- Abstract
Neprilysin (NEP) is a zinc metallopeptidase that efficiently degrades the amyloid β (Aβ) peptides believed to be involved in the etiology of Alzheimer disease (AD). The focus of this study was to develop a new and tractable therapeutic approach for treating AD using NEP gene therapy. We have introduced adeno-associated virus (AAV) expressing the mouse NEP gene into the hindlimb muscle of 6-month-old human amyloid precursor protein (hAPP) (3X-Tg-AD) mice, an age which correlates with early stage AD. Overexpression of NEP in muscle decreased brain soluble Aβ peptide levels by ~60% and decreased amyloid deposits by ~50%, with no apparent adverse effects. Expression of NEP on muscle did not affect the levels of a number of other physiological peptides known to be in vitro substrates. These findings demonstrate that peripheral expression of NEP and likely other peptidases represents an alternative to direct administration into brain and illustrates the potential for using NEP expression in muscle for the prevention and treatment of AD.Molecular Therapy (2009) 17 8, 1381–1386. doi:10.1038/mt.2009.115
- Subjects
GENE expression; PROTEOLYTIC enzymes; GENE therapy; AMYLOID; ALZHEIMER'S disease; TRANSGENIC mice
- Publication
Molecular Therapy, 2009, Vol 17, Issue 8, p1381
- ISSN
1525-0016
- Publication type
Article
- DOI
10.1038/mt.2009.115